ONCOLYTIC VIRAL VECTORS AND THEIR APPLICATION Russian patent published in 2022 - IPC C12N7/00 C12N15/86 A61K35/763 C12N9/22 

FIELD: biotechnology.

SUBSTANCE: recombinant oncolytic herpes simplex virus (HSV) for the treatment of cancer is claimed, containing (i) the first cassette of a microRNA target sequence (hereinafter – miR-TS cassette) inserted into the first viral gene and containing at least 2 target sequences for each of miR-124, miR-1 and miR-143, (ii) the second miR-TS cassette inserted into the second viral gene and containing at least 2 target sequences for each of miR-128, miR-219a and miR-122, and (iii) the third miR-TS cassette inserted into the third viral gene and containing at least 2 target sequences for each of miR-219a, miR-204 and miR-128. A nucleic acid molecule encoding an oncolytic virus, a viral drain for cancer treatment containing an oncolytic virus, and a composition for cancer treatment containing therapeutically effective amount of the claimed oncolytic virus are claimed. A method for destroying a cancer cell is claimed, including exposure to cancer cells of the claimed oncolytic virus, as well as a method for the treatment of cancer in a subject who needs it, including the injection of the claimed oncolytic virus.

EFFECT: invention makes it possible to use the claimed recombinant oncolytic herpes simplex virus (HSV) for the treatment of cancer.

38 cl, 25 tbl, 100 dwg, 16 ex